Drug intelligence / Profile preview

3,8-diamino-6-phenyl-5-[6-[1-[2-[(1,2,3,4-tetrahydro-9-acridinyl)amino]ethyl]-1h-1,2,3-triazol-4-yl]hexyl]-phenanthridinium

Development stage
Unknown
Modality
Small Molecules
01

Overview

This compound is a synthetic small molecule with the molecular formula C42H45N8+ and a molecular weight of approximately 661.9 g/mol[1][2][5]. It features a phenanthridinium core substituted with diamine and phenyl groups as well as an acridinyl-amino triazole-linked hexyl side chain[5]. The structure is related to DNA intercalators and fluorescent dyes but this specific compound is primarily referenced in chemical biology databases as an experimental or research tool rather than a marketed pharmaceutical agent[5][4]. There are no approved medical indications or clinical trial data for therapeutic use; it has been catalogued in DrugBank (DB03005), ChEMBL (CHEMBL540657), and PubChem (CID 5289507/5289508)[5][1][2]. Its mechanism of action has not been explicitly described in public sources but by analogy to similar phenanthridinium derivatives it may act as a DNA intercalator or probe for biochemical assays.

Other names
3,8-DIAMINO-6-PHENYL-5-[6-[1-[2-[(1,2,3,4-TETRAHYDRO-9-ACRIDINYL)AMINO]ETHYL]-1H-1,2,3-TRIAZOL-4-YL]HEXYL]-PHENANTHRIDINIUM3,8-Diamino-6-phenyI-(6-(l-(2-(l ,2 ,3 ,4-tetrahydroacridin -9-yI)amino)ethyl)-lH-l ,2 ,3-triazol -4-yI )hexyl )phenanthridin -5-i um3,8-diamino–6–phenyl–5–[6–(1-{2–[(1.2.3.4-tetrahydroacridin–9—y|)amino]ethyl}—IH—l .ZJ-triazol—A-y|)hexyljphcnanthndm-S-iurn

Beyond the preview

Go deeper on 3,8-diamino-6-phenyl-5-[6-[1-[2-[(1,2,3,4-tetrahydro-9-acridinyl)amino]ethyl]-1h-1,2,3-triazol-4-yl]hexyl]-phenanthridinium.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 3,8-diamino-6-phenyl-5-[6-[1-[2-[(1,2,3,4-tetrahydro-9-acridinyl)amino]ethyl]-1h-1,2,3-triazol-4-yl]hexyl]-phenanthridinium.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call